Clinical and translational research on tesamorelin, an FDA-approved GHRH analog for HIV-associated lipodystrophy, and related metabolic studies.
Also called Tesamorelin, Egrifta, GHRH analog HIV lipodystrophy
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH).1
Tesamorelin has defined dosing and regulatory approval for selected indications.1 In people living with HIV with nonobese visceral adiposity, treatment with tesamorelin led to marked reductions in waist circumference, improved lipid levels, and enhanced functional well-being.2 In a 12-month double-blind, randomized trial of people with HIV and nonalcoholic fatty liver disease, tesamorelin (compared to placebo) reduced circulating markers of immune activation, decreasing concentrations of 13 proteins, including 4 chemokines, 2 cytokines, and 4 T-cell associated proteins.3 In a double-blind, placebo-controlled pilot trial of 22 subjects with baseline cognition ranging from normal to mild cognitive impairment, 10 weeks of treatment with a 1 mg low dose of tesamorelin was not directly linked with significant changes in study measures, although machine learning models identified potential treatment-related differences in areas of the brain related to cognitive function.4 Adverse effects of performance-enhancing peptides modulating the GH-IGF1 axis span endocrine and metabolic disturbances, fluid retention syndromes, musculoskeletal symptoms, and injection-site reactions.5
The TRIUMPH study (Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV) is a randomized controlled trial designed to examine the combined effect of exercise and tesamorelin on physical function in 100 sedentary older adults (aged 50-80 years) living with HIV who are frail or at risk for frailty and have excess abdominal adiposity.1
Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post‐Administration Human Urine and Serum Using LC‐HRMS/MS
Drug Testing and Analysis — Colpaert T — Nov 2026
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
Sexual Medicine Reviews — Vasylieva V — Sep 2026
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
BMJ Open — Erlandson K — Jul 2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology — Dominikowski A — Jun 2026
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment
eNeurologicalSci — Stewart C — Jun 2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
JBJS Reviews — Meza A — May 2026
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Clinical Infectious Diseases — Beach R — Feb 2026
Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss
Journal of Clinical Medicine — Arora G — Jan 2026
P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants
Open Forum Infectious Diseases — Caldji C — Jan 2026
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis
Journal of the International Association of Providers of AIDS Care (JIAPAC) — Ditta A — Jan 2026
Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Drug Design Development and Therapy — Fraile J
166 citations · 2021 · among the most cited on Tesamorelin
Advances in the detection of growth hormone releasing hormone synthetic analogs
Drug Testing and Analysis — Memdouh S
22 citations · 2021 · among the most cited on Tesamorelin
Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease
Clinical Infectious Diseases — Stanley T
18 citations · 2021 · among the most cited on Tesamorelin
Causes and outcomes of hepatic fibrosis in persons living with HIV
Current Opinion in HIV and AIDS — Yen D
14 citations · 2022 · among the most cited on Tesamorelin
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
The American Journal of Sports Medicine — Mayfield C
13 citations · 2026 · among the most cited on Tesamorelin
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.